Blinatumomab (Figure 1) is a novel BiTE that can simultaneously bind to CD3 on T cells and CD19 on the surface of B-ALL cells, thereby activating T cells to kill tumor cells (Figure 5) [76]. This evidence concerns the gene CD19 and neoplasm.